Myriad Genetics to Announce Financial Results for the Fiscal Fourth Quarter and Full Year 2014 on August 12, 2014

Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal fourth quarter and full year 2014 as well as provide financial guidance for fiscal year 2015 following the close of market on Tuesday, August 12, 2014.

The Company also will host a conference call at 4:30 p.m. ET on August 12, 2014 to discuss the financial results. Participating on the call will be Peter Meldrum, president and CEO; Mark Capone, president of Myriad Genetic Laboratories, Inc., and James Evans, chief financial officer.

To listen to the call, interested parties in the United States may dial 800-707-7427 or [phone] for international callers.  All callers will be asked to reference reservation number 21728148.

The conference call also will be available through a live webcast at www.myriad.com. A replay of the call will be available two hours after the end of the call for seven days and may be accessed by dialing 800-633-8284 within the United States or [phone] for international callers and entering reservation number 21728148.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo and Myriad myRisk Hereditary Cancer, are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G.

CONTACT: Media Contact:
         Ron Rogers
         [phone]
         [e-mail]
         
         Investor Contact:
         Scott Gleason
         [phone]
         [e-mail]